THALIDOMIDE OPNIEUW IN DE BELANGSTELLING

L. T.W. De Jong-van Den Berg; J. Rutgers; M. C. Cornel

THALIDOMIDE OPNIEUW IN DE BELANGSTELLING

Translated title of the contribution: Renewed interest in thalidomide

L. T.W. De Jong-van Den Berg, J. Rutgers, M. C. Cornel

Research output: Contribution to journal › Article › Academic › peer-review

1 Citation (Scopus)

Abstract

Thalidomide was withdrawn from the market in the early sixties because of major teratogenic effects such as reduction defects of the limbs. Since. however, it has been found to be an effective drug in erythema nodosum leprosum. In the United States it was decided in September 1997 to admit thalidomide to the market for this indication, and in South America it has been available for this indication all the time. Thalidomide is also efficacious in other major disorders (e.g. aphtae and ulcers in aids) or its efficacy is being investigated in clinical trials (e.g. autoimmune diseases, other complications in aids:). The American Food and Drug Administration has imposed conditions for the use of thalidomide. Users have to sign an informed consent and to take adequate contraceptive measures. Physicians should inform the patients and monitor side effects. Pharmacists should record and control the use.

Translated title of the contribution	Renewed interest in thalidomide
Original language	Dutch
Pages (from-to)	1762-1765
Number of pages	4
Journal	Pharmaceutisch Weekblad
Volume	133
Issue number	47
Publication status	Published - 20 Nov 1998
Externally published	Yes

Keywords

Erythema nodosum leprosum
Precautions
Teratogens
Thalidomide
United States Food and Drug Administration

Cite this

@article{db0c58185b394459ae6c5ef7a2ebebf0,

title = "THALIDOMIDE OPNIEUW IN DE BELANGSTELLING",

abstract = "Thalidomide was withdrawn from the market in the early sixties because of major teratogenic effects such as reduction defects of the limbs. Since. however, it has been found to be an effective drug in erythema nodosum leprosum. In the United States it was decided in September 1997 to admit thalidomide to the market for this indication, and in South America it has been available for this indication all the time. Thalidomide is also efficacious in other major disorders (e.g. aphtae and ulcers in aids) or its efficacy is being investigated in clinical trials (e.g. autoimmune diseases, other complications in aids:). The American Food and Drug Administration has imposed conditions for the use of thalidomide. Users have to sign an informed consent and to take adequate contraceptive measures. Physicians should inform the patients and monitor side effects. Pharmacists should record and control the use.",

keywords = "Erythema nodosum leprosum, Precautions, Teratogens, Thalidomide, United States Food and Drug Administration",

author = "{De Jong-van Den Berg}, {L. T.W.} and J. Rutgers and Cornel, {M. C.}",

year = "1998",

month = nov,

day = "20",

language = "Dutch",

volume = "133",

pages = "1762--1765",

journal = "Pharmaceutisch Weekblad",

issn = "0031-6911",

publisher = "Koninklijke Nederlandse Maatschappij ter bevordering der Pharmacie",

number = "47",

}

TY - JOUR

T1 - THALIDOMIDE OPNIEUW IN DE BELANGSTELLING

AU - De Jong-van Den Berg, L. T.W.

AU - Rutgers, J.

AU - Cornel, M. C.

PY - 1998/11/20

Y1 - 1998/11/20

N2 - Thalidomide was withdrawn from the market in the early sixties because of major teratogenic effects such as reduction defects of the limbs. Since. however, it has been found to be an effective drug in erythema nodosum leprosum. In the United States it was decided in September 1997 to admit thalidomide to the market for this indication, and in South America it has been available for this indication all the time. Thalidomide is also efficacious in other major disorders (e.g. aphtae and ulcers in aids) or its efficacy is being investigated in clinical trials (e.g. autoimmune diseases, other complications in aids:). The American Food and Drug Administration has imposed conditions for the use of thalidomide. Users have to sign an informed consent and to take adequate contraceptive measures. Physicians should inform the patients and monitor side effects. Pharmacists should record and control the use.

AB - Thalidomide was withdrawn from the market in the early sixties because of major teratogenic effects such as reduction defects of the limbs. Since. however, it has been found to be an effective drug in erythema nodosum leprosum. In the United States it was decided in September 1997 to admit thalidomide to the market for this indication, and in South America it has been available for this indication all the time. Thalidomide is also efficacious in other major disorders (e.g. aphtae and ulcers in aids) or its efficacy is being investigated in clinical trials (e.g. autoimmune diseases, other complications in aids:). The American Food and Drug Administration has imposed conditions for the use of thalidomide. Users have to sign an informed consent and to take adequate contraceptive measures. Physicians should inform the patients and monitor side effects. Pharmacists should record and control the use.

KW - Erythema nodosum leprosum

KW - Precautions

KW - Teratogens

KW - Thalidomide

KW - United States Food and Drug Administration

UR - http://www.scopus.com/inward/record.url?scp=7844230220&partnerID=8YFLogxK

M3 - Article

SN - 0031-6911

VL - 133

SP - 1762

EP - 1765

JO - Pharmaceutisch Weekblad

JF - Pharmaceutisch Weekblad

IS - 47

ER -

THALIDOMIDE OPNIEUW IN DE BELANGSTELLING

Abstract

Keywords

Other files and links

Cite this